Blog - Page 906 of 5707 - QualityStocks

TuesdayAug 30, 2022 11:31 am

QualityStocksNewsBreaks – Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Partners with IBN for Corporate Communications

Cerberus Cyber Sentinel (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, has selected InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, as its communications partner. Cerberus Sentinel has developed an integrated approach to help clients enjoy a simpler and more successful journey to cyber resilience. The company is rapidly expanding by acquiring world-class cybersecurity and compliance businesses with top-tier talent that offer the latest technology to create innovative protection solutions. IBN offers an investor-based distribution network of more than 5,000 syndication outlets along with newsletters, social media channels, wire services,…

TuesdayAug 30, 2022 11:15 am

GeoSolar Technologies Inc.’s SmartGreen(TM) Tech Transforms Homes, Enables Energy Independence

GeoSolar goes beyond solar panel installation to provide complete home energy makeovers that can eliminate utility bills, provide energy independence GeoSolar’s SmartGreen(TM) technology produces energy through rooftop photovoltaic (“PV”) solar systems and geothermal ground loops Additional system customizations include tightening building envelope, insulation upgrades, LED lighting replacement, and EV charging infrastructure SEC recently qualified GeoSolar for Regulation A+ capital raise GeoSolar Technologies (“GST”), a Colorado-based climate technology company, goes beyond solar panel installation to provide complete building “green energy” makeovers that redefine power generation, utility, and conservation. GeoSolar’s SmartGreen(TM) energy technology leverages the power of the earth and sun to…

TuesdayAug 30, 2022 10:44 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To…

TuesdayAug 30, 2022 10:30 am

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) Seeks to Address Electric Vehicle Energy Efficiency Issues Through Proprietary Powertrain Solution

Electric vehicle charging infrastructure can be notorious for its efficiency losses, with onboard car chargers habitually losing 14% or more of the energy put into the vehicle Hillcrest Energy Technologies has looked to address that issue through the release of their simplified EV charger solution The traction inverter market is projected to reach $7 billion by 2025 at a CAGR of 17.57% due to increased demand for EV’s Electric vehicle (“EV”) owners are currently living through a scenario not entirely dissimilar to that being borne by their internal combustion engine vehicle driving counterparts. Over the past year, several car-charging operations…

TuesdayAug 30, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces the Availability of a Broadcast titled, “The Power of Science to Stop a Killer”

Lexaria’s latest broadcast highlights the company’s progress in finding a potential solution for hypertension treatment while also pointing out why such a solution is much needed at this point Since the company began developing its patented DehydraTECH(TM) technology in 2014, it has made significant progress in its clinical studies, even as it currently focuses on human clinical research to evaluate the tolerability, safety, and efficacy of its solution for hypertension treatment Lexaria expressed its confidence in its proposed solution, noting that it will not only be a safer but also better-tolerated drug candidate, unlike current alternatives in the market whose…

TuesdayAug 30, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”) GBM is an aggressive form of cancer that occurs in the brain or spinal cord In the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from its diagnosis CNS’s drug development program is targeting the GBM drug market which is expected to expand at a CAGR of more than 4% between 2020 and 2030 On July 24, 2021, pre-clinical…

MondayAug 29, 2022 1:43 pm

QualityStocksNewsBreaks – Cepton Inc. (NASDAQ: CPTN) Taking MMT(R) Mainstream, Focusing Efforts on ‘Biggest Market for Lidar’

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is taking Micro Motion Technology (“MMT(R)”) mainstream under the guidance of CEO and lidar pioneer Dr. Jun Pei. “Lidar uses lasers to generate 3D images and provides vital information including distance, speed and dimensions. This enables accurate detection tracking of objects based on real-time data. Emerging lidar applications include autonomous vehicles (‘AVs’), advanced driver assistance systems (‘ADAS’), traffic and pedestrian monitoring in smart cities, security and facility management, crowd analytics, and various industrial applications,” a recent article reads. “Cepton offers near-range to ultra-long-range lidar sensors, automotive software…

MondayAug 29, 2022 1:29 pm

QualityStocksNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Streamlining NAFTA Region’s Cross-Border Shipping Process

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), through its Fr8App platform, offers a cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. Innovative solutions offer quick and safe cross-border shipments while streamlining daily carrier operations. “The platform functions just as well for domestic, intra-country operations in each of the countries of the United States of America, Mexico or Canada. Because of this and other offerings in the Fr8Tech solutions suite, including but not limited to Fr8Radar, Fr8TMS and Fr8FMS, the company has come to be known for developing solutions to optimize and automate the supply chain process, offering…

MondayAug 29, 2022 12:18 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned 1:1 to 1 dose of PRV-003 or placebo for five consecutive days,” the article reads. “Evaluated by the Safety Review Committee, no serious adverse events were recorded, and all patients demonstrated normal vital signs, electrocardiogram…

MondayAug 29, 2022 12:00 pm

Strong Earnings, Revenue Reports from Plant-based Foods Maker Belle Pulses, Drives Cheery Assessment for Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

Plant-based foods investment company Eat Well Investment Group Inc. recently released its Q2 financial report for its Belle Pulses subsidiary, showing record growth in key market segments Belle Pulses’ revenues grew 6.8 percent YOY to $15.17 million The company’s gross profit grew by 59.6 percent to $2 million Belle’s net earnings grew a whopping 295.8 percent YOY to $1.37 million Belle Pulses is 100 percent owned by Eat Well, along with plant-based snack food developer Sapientia Sapientia and Eat Well’s other subsidiary, baby food maker Amara, are poised to increase distribution outlets as their profiles grow Eat Well Investment Group…

Site Search

Company Search